公开(公告)号：US20220127305A1

公开(公告)日：2022-04-28

申请号：US17572115

申请日：2022-01-10

申请人： IPSEN PHARMA S.A.S.

发明人： Zheng Xin Dong ,  Jacques-Pierre Moreau

IPC分类号： C07K7/06 ,  C07K7/08 ,  C07K14/665

摘要： The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

公开(公告)号：US10787696B2

公开(公告)日：2020-09-29

申请号：US14026014

申请日：2013-09-13

申请人： IPSEN PHARMA S.A.S.

发明人： George A. Oyler ,  Yung-Nien Chang ,  Yien Che Tsai

IPC分类号： C12Q1/37 ,  C12Q1/6897 ,  C12N15/63 ,  C12N15/10

摘要： A system for the identification of proteases and protease inhibitors is provided. The system has at least two components. The first component is a reporter construct with at least one binding site, a transcriptional promoter, an inducible promoter region, and at least one reporter gene, all functionally connected for expression of the reporter gene(s) in functional coordination with a transcriptional activation agent. The second component is a transcriptional activation agent comprising a nucleic acid binding domain, at least one protease substrate domain, and at least one transcriptional activation domain for an inducible promoter. The system allows detection and evaluation of agents affecting protease activity directed to the protease substrate domain. The system also allows for the detection of the presence of proteases in environmental samples.

公开(公告)号：US10206968B2

公开(公告)日：2019-02-19

申请号：US15139533

申请日：2016-04-27

申请人： IPSEN PHARMA S.A.S.

发明人： Martin Montes ,  Thomas Ciaran Loughman ,  Chantal Roume ,  Roland Cherif-Cheikh

IPC分类号： A61K38/08 ,  A61K9/00 ,  A61K9/19 ,  A61K38/31 ,  A61K47/12 ,  A61K38/12

摘要： A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogs and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and acetic acid to form a lyophilizate and hydrating the lyophilizate, wherein the lyophilization is performed only once.

公开(公告)号：US20180118784A1

公开(公告)日：2018-05-03

申请号：US15688959

申请日：2017-08-29

申请人： Ipsen Pharma S.A.S.

发明人： Zheng Xin DONG ,  Daniel B. DEOLIVEIRA ,  Jeanne Mary COMSTOCK

IPC分类号： C07K7/06 ,  C07K14/68 ,  C07K7/56 ,  A61K38/00

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/56 ,  C07K14/68

摘要： The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.

公开(公告)号：US09918967B2

公开(公告)日：2018-03-20

申请号：US14640712

申请日：2015-03-06

申请人： Ipsen Pharma S.A.S.

发明人： Pierre-Etienne Chabrier de Lassauniere ,  Michel Auguet ,  Brigitte Spinnewyn

IPC分类号： A61K31/426 ,  A61K31/427 ,  A61K31/198 ,  C07D277/28

CPC分类号： A61K31/426 ,  A61K31/198 ,  A61K31/427 ,  C07D277/28

摘要： The invention relates to the use of derivatives of thiazoles having general formula (I) for the preparation of a medicament for the treatment or prevention of dyskinesias caused by a chemical treatment. The invention also relates to a combination of thiazole derivatives having general formula (I) and at least one compound selected from among neuroleptics or products that act on the dopaminergic system for the treatment or prevention of dyskinesias caused by a chemical treatment.

公开(公告)号：US09850280B2

公开(公告)日：2017-12-26

申请号：US15587426

申请日：2017-05-05

申请人： Ipsen Pharma S.A.S.

发明人： Zheng Xin Dong ,  Jacques-Pierre Moreau

IPC分类号： A61K38/00 ,  C07K7/00 ,  C07K7/06

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/08 ,  C07K14/665

摘要： The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

公开(公告)号：US09724397B2

公开(公告)日：2017-08-08

申请号：US12447431

申请日：2007-10-26

申请人： Roland Cherif-Cheikh ,  Anne-Paula De Sousa Delgado ,  Frédéric Lacombe ,  Laurence Lachamp ,  Didier Bourissou

发明人： Roland Cherif-Cheikh ,  Anne-Paula De Sousa Delgado ,  Frédéric Lacombe ,  Laurence Lachamp ,  Didier Bourissou

IPC分类号： A61F13/00 ,  A61K38/09 ,  A61K38/30 ,  A61K9/00 ,  A61K38/25 ,  A61K38/26 ,  A61K38/27 ,  A61K47/34 ,  A61K47/36

CPC分类号： A61K38/30 ,  A61K9/0024 ,  A61K38/09 ,  A61K38/25 ,  A61K38/26 ,  A61K38/27 ,  A61K47/34 ,  A61K47/36

摘要： The present invention relates to a parenteral, sustained and controlled release, semisolid formulation comprising an end-capped oligomer and at least one active substance without any supplementary viscosity reducing agent or excipient.

公开(公告)号：US09603942B2

公开(公告)日：2017-03-28

申请号：US14614458

申请日：2015-02-05

申请人： Ipsen Pharma S.A.S.

发明人： Zheng Xin Dong ,  Yeelana Shen

IPC分类号： A61K38/00 ,  A61P35/00 ,  A61K38/12 ,  A61K38/08 ,  A61K38/31 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K38/04 ,  A61K47/48 ,  C07K14/655 ,  C07K19/00 ,  C07C215/52

CPC分类号： A61K47/64 ,  A61K38/00 ,  A61K38/31 ,  A61K47/55 ,  C07C215/52 ,  C07K14/655 ,  C07K19/00

摘要： The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.

公开(公告)号：US20160206700A1

公开(公告)日：2016-07-21

申请号：US14997678

申请日：2016-01-18

申请人： Ipsen Pharma S.A.S.

发明人： Zheng Xin Dong ,  John E. Taylor ,  Rakesh Datta ,  Michael DeWitt Culler

IPC分类号： A61K38/22 ,  A61K38/06 ,  A61K38/05

CPC分类号： A61K38/22 ,  A61K38/05 ,  A61K38/06 ,  A61K38/25 ,  C07K7/06 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y02A50/463 ,  Y02A50/475 ,  Y02A50/484

摘要： The present invention provides a method of ameliorating inflammation, inhibiting proinflammatory cytokine and/or chemokine expression and treating various diseases and/or conditions incidental to the onset of inflammation, in a subject in need of treatment for such conditions, by administering select analogues of native hGhrelin.

公开(公告)号：US09352012B2

公开(公告)日：2016-05-31

申请号：US13522297

申请日：2011-01-11

申请人： Martin Montes ,  Thomas Ciaran Loughman ,  Chantal Roume ,  Roland Cherif-Cheikh

发明人： Martin Montes ,  Thomas Ciaran Loughman ,  Chantal Roume ,  Roland Cherif-Cheikh

IPC分类号： A61K38/31 ,  A61K38/12 ,  C07K7/50 ,  A61K9/19 ,  A61K9/00 ,  A61K47/12

CPC分类号： A61K38/08 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/12 ,  A61K38/31 ,  A61K47/12

摘要： The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.

摘要翻译： 本发明涉及制备用于持续释放生长抑素类似物的可注射药物组合物和根据该方法制备的药物组合物的方法。 在优选的方面，该方法包括以下步骤：将醋酸兰曲肽和乙酸组合，将所得混合物冻干一次，并使冻干物水合。 在该方法的最后步骤期间可以将乙酸加入到所需的pH值。